FDA Approves the First Gene Therapy for GSDIa

For a disease with no treatment aimed at its cause, only its symptoms, FDA has now approved one. On 19 August 2026, FDA granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec-opnr) — the first gene therapy, and the first FDA-approved treatment of any kind, designed to address the underlying cause of glycogen storage disease type Ia (GSDIa) rather than manage around it. Patients with GSDIa have relied for decades on strict, round-the-clock cornstarch dosing to prevent dangerous drops in blood sugar; Genglycos is a single infusion aimed at reducing that burden, not eliminating the disease's biochemistry.

What GSDIa is, and why cornstarch has been the only lever

GSDIa is caused by biallelic pathogenic variants in the G6PC gene, which leaves patients deficient in glucose-6-phosphatase — the enzyme that lets the liver convert stored glycogen back into usable glucose. Without it, patients face severe hypoglycemia within hours of fasting, along with lactic acidosis, hyperlipidemia and hyperuricemia. Management has historically meant frequent, precisely timed doses of uncooked cornstarch, day and night, for life — a regimen that controls blood sugar but treats none of the underlying enzyme deficiency. Roughly 6,000 people worldwide are estimated to have the condition, small enough that no drug developer had previously brought a therapy targeting the biochemistry itself through to approval.

The mechanism and the trial data

Genglycos uses an adeno-associated virus serotype 8 (AAV8) vector to deliver a codon-optimized copy of the human G6PC gene directly to liver cells in a single intravenous infusion, restoring enzyme function rather than compensating for its absence. In the pivotal GlucoGene study — a 48-week, randomized, double-blind, placebo-controlled trial in 46 patients age 8 and older — treatment produced a mean 41.3% reduction in daily cornstarch intake, against 10.3% in the placebo arm, a difference FDA and Ultragenyx both describe as statistically significant (p<0.0001) and clinically meaningful. Safety findings centered on transient, steroid-responsive elevations in liver enzymes, a signal consistent with other AAV-vectored liver-directed gene therapies rather than a GSDIa-specific concern.

What accelerated approval actually commits Ultragenyx to

• The trade-off: accelerated approval lets a sponsor market a product on evidence considered reasonably likely to predict clinical benefit — here, reduced cornstarch dependence — ahead of long-term outcome data, in exchange for a binding confirmatory commitment.
• The commitment: two years of safety and efficacy data collected from patients receiving Genglycos in open-label commercial use.
• The comparator: a control group made up of patients who are clinically eligible for GSDIa but cannot receive Genglycos because they test positive for pre-existing anti-AAV8 antibodies, which block the therapy's viral vector from working — effectively a natural, if imperfect, untreated comparison group.
• The incentive: the approval qualifies for a Rare Pediatric Disease Priority Review Voucher, which Ultragenyx can use to speed review of a future application of its own or sell to another sponsor.

What practitioners should watch next

The regulatory story here is really about the confirmatory-evidence structure, not just the approval itself. Anti-AAV8 seropositivity is common enough in the general population that it functions as a built-in exclusion criterion — patients who test positive cannot be treated, which is precisely what makes them useful as an unenrolled comparison group for the post-marketing commitment. Whether that comparison holds up scientifically, and whether the 41.3%-versus-10.3% cornstarch reduction translates into fewer hypoglycemic events over years rather than weeks, is the evidence FDA will be watching for over the life of this accelerated approval. For a company whose commercial base has been built on ultra-rare-disease therapies, Genglycos is also the first product to test whether that model extends to gene therapy specifically.